2024 Platinum resistant ovarian cancer orr

Platinum resistant ovarian cancer orr

Author: xkmm

August undefined, 2024

Webb13 apr. 2024 · The ORR of platinum-resistance recurrent patients in this study was 39%. Among these 41 patients, 26.8% ... Which non-platinum single agent combined with … Webb28 aug. 2024 · Platinum-resistant OC is a dismal disease and has a low response to subsequent chemotherapy. In this study, we found that the pooled ORR was 25% in …

Treatment options for recurrent platinum-resistant ovarian cancer: …

Webb23 juli 2024 · “We are very encouraged by the potential of AVB-500 to improve responses and progression free survival in combination with chemotherapy in platinum resistant ovarian cancer. The information we have obtained from the clinical data together with some informal preliminary feedback from the FDA have helped inform our Phase 2/3 trial … WebbBackground: Licensed systemic treatment options for platinum-sensitive recurrent ovarian cancer are platinum-based chemotherapy and maintenance treatment with bevacizumab … synonyms for brute force

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With ...

Webb14 nov. 2024 · Efficacy was evaluated in Study 0417 (NCT04296890), a single-arm trial of 106 patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or … WebbPlatinum-sensitive or platinum-resistant. If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6–12 months after last treatment, and platinum-resistant cancers have an interval of less than ... synonyms for bu

SORAYA Trial Meets Primary End Point of ORR in Ovarian Cancer

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian …

WebbAll platinum-resistant ovarian cancer patients treated with anlotinib between June 2024 and September 2024 in Jiangsu Cancer Hospital were included. ... It has been confirmed … Webb1 juni 2024 · Purpose: Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. Methods: Eligibility criteria included measurable disease, 1-3 prior regimens, and platinum-free interval (PFI) < 12 months. synonyms for buckshotWebbIntroduction. Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancy in the Western World. It is the seventh most common cancer … thai thai villa huntington new york

"WebbApatinib is an oral and highly potent tyrosine-kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). 5 Efficacy and safety of apatinib in patients with platinum-resistant recurrent epithelial ovarian cancer (PROC) were shown in phase II clinical trials. 6 Besides, apatinib combined with oral etoposide was proved to be … " - Platinum resistant ovarian cancer orr

Platinum resistant ovarian cancer orr

IJMS Free Full-Text The Current Status of DNA-Repair-Directed ...

Webb5 jan. 2024 · Abstract Purpose: Platinum-resistant ovarian cancer (PROC) is usually treated with single-agent chemotherapy. A synergistic effect of gemcitabine and platinum has … Webb3 dec. 2024 · In this trial, patients with recurrent platinum-sensitive ovarian cancer who had at least 2 prior lines of chemotherapy and had a complete or partial response to the last platinum-based treatment were randomized to receive rucaparib or placebo maintenance.

Did you know?

Webb15 dec. 2024 · Two phase II trials have tested this concept in people with platinum-resistant and unresponsive ovarian cancer. One, run by Dana-Farber and NCI researchers, tested a compound that blocks... Webb13 apr. 2024 · The ORR of platinum-resistance recurrent patients in this study was 39%. Among these 41 patients, 26.8% ... Which non-platinum single agent combined with bevacizumab has better efficacy in the treatment of platinum-resistant recurrent ovarian cancer needs to be further verified by randomized controlled trials with a larger sample …

WebbObjective: Our objective was to assess safety and adverse events associated with intraperitoneal Olvi-Vec virotherapy in patients with platinum-resistant or refractory … Webb10 nov. 2014 · The study enrolled 107 patients with both platinum-sensitive and platinum-resistant recurrent ovarian cancer at 67 clinical sites in the United States. Median PFS was 7.3 months for bevacizumab plus fosbretabulin (n=54) compared to 4.8 months with bevacizumab (n= 53).

WebbORR for single-agent chemotherapy reported in prior trials of PROC, which range from 4% to 13%.4-12 ... Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study Author: Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin, ... Webbpatients with platinum resistant ovarian cancer. Patients with platinum resistant ovarian carcinoma and measurable disease received canfosfamide at 960 mg/m2 in …

Webb25 mars 2024 · The agent also has been evaluated in combination with bevacizumab in the platinum-resistant, recurrent ovarian cancer setting. In a phase 1b trial, data showed that the ADC led to an ORR...

Webb20 mars 2024 · Liu noted that the majority of patients enrolled had BRCA wt or HRRwt tumors, and that 43.9% of patients had platinum-resistant disease, both of which are predictive factors associated with... thai thai village sushiWebb25 maj 2024 · 6061 Background: Recurrent platinum-resistant or refractory ovarian carcinoma is difficult to treat, and how to improve the treatment effect of these patients … thai thai visby menyWebb11 apr. 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be … synonyms for bubWebbPlatinum-resistant HGSOC patients received ceralasertib 160 mg orally daily, days 1-7 and olaparib 300 mg orally twice daily, days 1-28 of a 28-day cycle until toxicity or … thai thai village menuWebbVirus-induced changes in the tumor microenvironment may explain the apparent reversal of platinum resistance. Clinical trial identification NCT02759588. Editorial acknowledgement None. Legal entity responsible for the study Genelux Corporation, San Diego, CA, USA. Funding Genelux Corporation, San Diego, CA, USA. Disclosure thai thai villa huntington menuWebbGrade 3–4 thrombocytopenia (41.9%) and febrile neutropenia (19.4%) were also seen. The results showed that cisplatin combined with topotecan, as second- or higher-line palliative chemotherapy for patients with advanced or recurrent ovarian cancer, might be effective, especially in the platinum-sensitive group. thai thai westfield chodovWebbPurpose: Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab … thai thai volcano village